Global Bio-chem Technology Group Co. Ltd. (0809) AI Stock Analysis

• Market Cap: HK$819.48M
• Dividend Yield: N/A
• Average Volume (3M): 8.11M
• Price to Earnings (P/E): 1.1
• Beta (1Y): <0.01
• Revenue Growth: 45.65%
• EPS Growth: -81.70%
• Country: HK
• Employees: 1,567
• Sector: Basic Materials
• Sector Strength: 67
• Industry: Packaged Foods
• EPS (TTM): 0.10
• Shares Outstanding: 8,907,405,000
• 10 Day Avg. Volume: 9,794,600
• 30 Day Avg. Volume: 8,109,000
• PEG Ratio: -0.01
• Price to Book (P/B): -0.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -89.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: HK$0.00 ▼(-100.00%Downside)

The overall stock score is significantly influenced by financial instability, which poses considerable risks despite recent operational improvements. Technical indicators suggest moderate market interest, while the low P/E ratio indicates valuation potential. However, the lack of dividend yield limits income appeal.

Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model

Company Description

Global Bio-chem Technology Group Company Limited, an investment holding company, manufactures and sells corn refined products and corn-based biochemical products in the People's Republic of China, rest of Asia, the Americas, and internationally. It operates through four segments: Upstream Products, Amino Acids, Corn Sweeteners, and Polyol Chemicals. The company offers corn refined products, including corn oil, corn steep liquor, corn starch, waxy corn starch, corn gluten meal, feed pellets, and corn germ cake. It also provides downstream corn based biochemical products, such as amino acids comprising lysine, protein lysine, threonine, and glutamic acid; corn sweeteners, which include high fructose corn syrup, maltodextrin, high maltose syrup, maltose syrup, sorbitol, glucose, and crystallized glucose; modified starches; and chemicals comprising ethylene, propylene, and butylene glycols, as well as resins. In addition, the company offers anti-freeze products, hydrogen, and ammonia. Its products are used in various applications, such as feed production, food and beverage, cosmetics, textiles, pharmaceuticals, chemical industries, etc. The company was founded in 1994 and is headquartered in Hung Hom, Hong Kong.

How the Company Makes Money

Global Bio-chem Technology Group Co. Ltd. generates revenue primarily through the production and sale of its core bio-based products. The company operates an integrated business model that spans the entire value chain from raw material procurement to the final production of high-value products. Key revenue streams include the sale of amino acids, such as lysine and threonine, which are essential in animal nutrition, and corn sweeteners used in the food and beverage industry. Additionally, the company produces polyols, which find applications in the cosmetics and pharmaceuticals sectors. Strategic partnerships with agricultural suppliers and collaborations with industry leaders enhance the company's market presence and contribute to its financial performance.

Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview

Summary

Global Bio-chem Technology Group Co. Ltd. exhibits major financial instability with negative equity, high leverage, and inconsistent cash flows. While there are recent improvements in revenue and operating cash flow, the company remains at risk due to historical losses and financial distress.

Income Statement

The company shows significant volatility in revenue, with a recent increase from 2022 to 2023, but overall negative EBIT and net income suggest underlying profitability issues. The negative EBIT margin underscores operational challenges, while EBITDA margin turning positive in 2024 reflects some improvement in operating efficiency.

Balance Sheet

The company faces severe financial instability with negative stockholders' equity reflecting balance sheet insolvency, and a high debt-to-equity ratio indicating excessive leverage. The negative equity ratio further highlights financial distress, posing considerable risks.

Cash Flow

Cash flow from operations has improved from negative to positive in 2024, indicating better cash management. However, the free cash flow still faces challenges due to historical negative trends, and the operating cash flow to net income ratio is volatile, highlighting cash flow unpredictability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.00B	1.37B	372.28M	746.55M	848.87M
Gross Profit	218.68M	43.64M	34.60M	48.35M	74.10M
EBITDA	16.85M	4.69B	-469.06M	785.63M	-1.39B
Net Income	769.60M	4.22B	-1.52B	-435.39M	-2.43B
Balance Sheet
Total Assets	4.54B	5.21B	5.85B	6.48B	7.60B
Cash, Cash Equivalents and Short-Term Investments	149.43M	315.41M	41.77M	21.81M	153.32M
Total Debt	3.69B	5.45B	8.15B	8.44B	8.96B
Total Liabilities	6.50B	9.25B	13.64B	13.18B	13.62B
Stockholders Equity	-1.95B	-4.04B	-7.54B	-6.52B	-5.86B
Cash Flow
Free Cash Flow	76.04M	-94.24M	-94.19M	-501.02M	-43.02M
Operating Cash Flow	76.04M	-50.46M	-88.01M	-475.21M	-26.19M
Investing Cash Flow	-535.00K	-14.37M	-413.00K	392.59M	120.09M
Financing Cash Flow	-76.06M	165.81M	109.75M	-48.66M	-25.87M

Global Bio-chem Technology Group Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 49.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0809.

Global Bio-chem Technology Group Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2317	77 Outperform	HK$1.02B	8.15	5.39%	16.34%	-1.88%	129.25%
3838	65 Neutral	HK$1.36B	2.60	12.45%	23.11%	-5.08%	359.16%
1767	65 Neutral	HK$295.00M	7.99	8.18%	2.40%	>-0.01%	16.04%
0829	59 Neutral	HK$1.00B	34.83	1.14%	12.90%	-10.03%	-14.29%
0809	57 Neutral	HK$819.48M	1.11		―	45.65%	-81.70%
2147	51 Neutral	HK$41.44M	―	-12.63%	―	32.15%	-171.32%
Sector *	44 Neutral	AU$1.51B	-6.22	-41.37%	3.85%	-3.52%	-43.04%

Global Bio-chem Technology Group Co. Ltd. Corporate Events

Global Bio-chem Announces Debt Restructuring and Equity Re-acquisition

Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement involving the re-acquisition of equity interest in Century Dacheng. This arrangement includes a debt-to-equity conversion and an equity-swap, resulting in Century Dacheng becoming an indirect wholly-owned subsidiary of the company again. The restructuring will be settled through the issuance of Consideration Shares, which will significantly affect the company’s share capital. The completion of this arrangement is subject to approval at an Extraordinary General Meeting (EGM), where shareholders will vote on the re-acquisition and the issuance of the Consideration Shares.

Global Bio-chem Advances Debt Restructuring with Equity Swap and Supplier Settlements

Global Bio-chem Technology Group Co. Ltd. has announced the completion of a Debt-to-Equity-Swap Agreement, resulting in Suppliers PRC LLPs holding a 28.98% equity interest in Century Dacheng. The company is progressing with its Suppliers Debt Restructuring Arrangement, expected to conclude by the end of 2025, pending necessary approvals. Concurrently, the company has reached settlement agreements with 33 remaining suppliers involving a significant debt discount, resulting in a projected net gain of no less than HK$17.0 million. These strategic financial maneuvers are aimed at stabilizing the company’s financial position and enhancing its operational capabilities.

Global Bio-chem Initiates Debt Restructuring to Strengthen Financial Position

Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement to address overdue payables amounting to RMB461.1 million, involving over 130 independent suppliers. This arrangement includes a debt-to-equity conversion and an equity swap, ultimately allowing suppliers to convert their debt into equity in a subsidiary, Century Dacheng, and then into shares of the company. This strategic move is expected to result in a net gain of no less than HK$190.0 million for the company, improving its financial standing and potentially enhancing shareholder value.

Global Bio-chem Relaunches Boiler Refurbishment Project via Public Tender

Global Bio-chem Technology Group Co. Ltd. has announced the relaunch of the Boiler Refurbishment Project at Changchun Dahe, which involves entering into an EPC Contract through a public tender process. The tender, which commenced on May 26, 2025, will determine the contractor responsible for engineering design, procurement, and construction works. The project is significant as it may constitute a discloseable transaction under the Listing Rules, potentially impacting the company’s operations and market positioning.

Global Bio-chem Partners with Hefei Hechen to Boost Synthetic Biology

Global Bio-chem Technology Group Co. Ltd. has entered into a strategic cooperation framework agreement with Hefei Hechen Bio-tech Company Limited to establish a synthetic biology pilot testing platform at its Xinglongshan production site. This collaboration aims to leverage both companies’ strengths in synthetic biology to support the development of bio-manufacturing industries in Jilin Province. The initiative marks a significant step towards resuming operations at the Xinglongshan site, which is expected to improve operational efficiency and strengthen the company’s working capital.

Global Bio-chem Technology’s AGM Resolutions Approved

Global Bio-chem Technology Group Co. Ltd. announced that all resolutions proposed at its Annual General Meeting were approved by shareholders. The resolutions included the re-election of directors, approval of financial statements, and granting of mandates for share dealings, indicating strong shareholder support and potentially enhancing the company’s governance and operational flexibility.